Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

Envestnet Portfolio Solutions Inc. increased its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 7.9% in the 4th quarter, Holdings Channel reports. The firm owned 1,509 shares of the ...

"All three types of myasthenia gravis, based on antibody status ... In LRP4 disease, "false positives can be seen with motor neuron disease," he said. "I recommend always having neurophysiological ...

Multifocal Motor Neuropathy (MMN) Phase 2 MoMeNtum MMN trial ongoing ... reporting top-line data from the Phase 2 MaGic trial in generalized Myasthenia Gravis in 2H’25, the interim responder analysis ...

Farther Finance Advisors LLC grew its stake in shares of argenx SE (NASDAQ:ARGX – Free Report) by 38.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 76 shares ...

anticipated by YE’24 Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results anticipated in 2H’25 Phase 2 MoMeNtum trial of DNTH103 in Multifocal Motor ...

Drivers are being warned that failure to inform the DVLA about a health diagnosis, and any subsequent changes in health, can ...

carpal tunnel syndrome cervical and lumbar radiculopathy peripheral neuropathy myasthenia gravis motor neuron disease You also will participate in analyzing and interpreting data leading to ...

In November 2024, the company reported a Phase III flop for its myostatin and activin receptor blocker taldefgrobep alfa, which was unable to significantly boost motor function in spinal ...

Weakness in the legs can be due to a spine or leg injury, but other potential causes can include diabetic neuropathy, cancer, stroke, myasthenia gravis, and other underlying conditions. It is a common ...